

# RTI Health Solutions (RTI-HS)

**First published:** 21/04/2010

**Last updated:** 13/03/2025

**Institution**

**Not-for-profit**

## Institution identification

### Institution ID

48288

---

### Institution countries

- ☐ France
  - ☐ Spain
  - ☐ Sweden
  - ☐ United Kingdom
  - ☐ United Kingdom (Northern Ireland)
  - ☐ United States
- 

### Type of institution

Not-for-profit

---

### Institution website

<https://www.rtihs.org/services/pharmacoepidemiology-and-risk-management>

---

### ENCePP partner

Yes

## Institution description

RTI is an independent, non-profit research institute with history spanning over sixty-five years. Throughout this time, RTI has been leading research initiatives for both public and private organizations. One of its specialized units, RTI Health Solutions (RTI-HS), is dedicated to advancing pharmaceutical and health research. RTI-HS's areas of expertise include pharmacoepidemiology and real-world evidence (RWE), risk management, benefit-risk evaluation, pharmacovigilance, patient-reported outcomes, health preference assessment, implementation science, medical communications, and more. The team of experts at RTI-HS is located across Europe and the United States, ensuring a broad and diverse geographical spread.

RTI-HS holds a Clinical Practice Research Datalink (CPRD) license, which provides access to anonymized patient primary care data from a network of general practitioner practices in the United Kingdom. This enhances RTI-HS's capabilities in conducting high-quality, real-world research and generating valuable insights for healthcare decision-making.

RTI-HS's experts employ innovative methods in their research, including causal inference methods with target trial emulation and external control arm frameworks. These methodologies enable researchers to draw accurate conclusions about the safety and effectiveness of medicines, vaccines, and medical devices.

For a comprehensive list of RTI-HS publications, please visit [www.rtihs.org/publications](http://www.rtihs.org/publications)

## Institution details

**Experience with collecting data directly from individual patients or respondents:**

Yes

---

**Interest in carrying out research that is funded by pharmaceutical companies:**

Yes

# Contact

Carla Franzoni Grau [cfranzoni@rti.org](mailto:cfranzoni@rti.org)

**Main**

[cfranzoni@rti.org](mailto:cfranzoni@rti.org)

Susana Perez-Gutthann [sperez@rti.org](mailto:sperez@rti.org)

**Alternate**

[sperez@rti.org](mailto:sperez@rti.org)